Gail D’Onofrio, MD, MS, professor of emergency medicine and public health, and David Fiellin, MD, professor of medicine, emergency medicine, and public health, are lead investigators in a $25.5 Million study being conducted by the National Drug Abuse Treatment Clinical Trials Network’s New England Consortium Node (PIs: Roger Weiss MD, McLean Hospital/Harvard Medical School and Kathleen Carroll PhD, Department of Psychiatry, Yale School of Medicine). The Emergency Department-Initiated buprenorphine Validation Network Trial (ED-INNOVATION) involves 30 diverse emergency departments (EDs) throughout the U.S.
The investigators will test an implementation strategy to guide the development of ED-initiated treatment of opioid use disorder with buprenorphine programs at the sites, and subsequently compare the effectiveness of two formulations of buprenorphine, sublingual versus an extended release 7-day injectable formulation in engaging ED patients with untreated opioid use disorder in medication treatment at 7 days. In addition, Dr. Andrew Taylor, Assistant Professor of Emergency Medicine, will lead a study developing and validating opioid use disorder phenotypes to better identify and characterize opioid use disorder in EDs. Other Yale investigators include Kathryn Hawk MD, James Dziura PhD, Michael Pantalon PhD, Arjun Venkatesh MD and Edouard Coupet MD from the Department of Emergency Medicine and Paul Joudrey MD, Jennifer Edelman MD, Patrick O’Connor MD, from the Department of Medicine.